You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZolpidem
Accession NumberDB00425  (APRD00095)
TypeSmall Molecule
GroupsApproved
Description

Zolpidem is a prescription short-acting nonbenzodiazepine hypnotic that potentiates gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, by binding to benzodiazepine receptors which are located on the gamma-aminobutyric acid receptors. Zolpidem is used for the short-term treatment of insomnia. It works quickly (usually within 15 minutes) and has a short half-life (2-3 hours). It is classified as an imidazopyridine. As an anticonvulsant and muscle relaxant, the beneficial effects start to emerge at 10 and 20 times the dose required for sedation, respectively. For that reason, it has never been approved for either muscle relaxation or seizure prevention. Recently, zolpidem has been cited in various medical reports mainly in the United Kingdom as waking persistent vegetative state (PVS) patients, and dramatically improving the conditions of people with brain injuries. [Wikipedia]

Structure
Thumb
Synonyms
N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide
Zolpidem
Zolpidemum
External Identifiers
  • HSDB 7045
  • SL 800750
  • SL 800750-23N
  • UNII-7K383OQI23
  • UNII-WY6W63843K
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ambientablet, film coated10 mg/1oralbryant ranch prepack1993-04-01Not applicableUs
Ambientablet, film coated5 mg/1oralSanofi Aventis U.S. Llc1993-04-01Not applicableUs
Ambientablet, film coated10 mg/1oralA S Medication Solutions Llc1993-04-01Not applicableUs
Ambientablet, film coated10 mg/1oralRebel Distributors Corp.2009-06-30Not applicableUs
Ambientablet, film coated5 mg/1oralA S Medication Solutions Llc1993-04-01Not applicableUs
Ambientablet, film coated5 mg/1oralRebel Distributors Corp.2009-06-30Not applicableUs
Ambientablet, film coated10 mg/1oralA S Medication Solutions Llc1993-04-01Not applicableUs
Ambientablet, film coated5 mg/1oralA S Medication Solutions Llc1993-04-01Not applicableUs
Ambientablet, film coated10 mg/1oralSTAT Rx USA LLC1993-04-01Not applicableUs
Ambientablet, film coated5 mg/1oralSTAT Rx USA LLC1993-04-01Not applicableUs
Ambientablet, film coated10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2009-06-30Not applicableUs
Ambientablet, film coated10 mg/1oralSanofi Aventis U.S. Llc1993-04-01Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralRebel Distributors Corp.2009-06-30Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralSt Marys Medical Park Pharmacy2010-12-01Not applicableUs
Ambien CRtablet, coated6.25 mg/1oralRebel Distributors Corp.2009-06-30Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralSTAT Rx USA LLC2009-06-30Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralPd Rx Pharmaceuticals, Inc.2009-06-30Not applicableUs
Ambien CRtablet6.25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-10Not applicableUs
Ambien CRtablet, coated6.25 mg/1oralPhysicians Total Care, Inc.2005-10-07Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-13Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralSanofi Aventis U.S. Llc2005-09-19Not applicableUs
Ambien CRtablet, coated6.25 mg/1oralbryant ranch prepack2009-06-30Not applicableUs
Ambien CRtablet, coated6.25 mg/1oralSanofi Aventis U.S. Llc2005-09-19Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralPhysicians Total Care, Inc.2009-11-24Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralbryant ranch prepack2009-06-30Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralA S Medication Solutions Llc2005-09-19Not applicableUs
Edluartablet5 mg/1oralMeda Pharmaceuticals Inc.2009-07-24Not applicableUs
Edluartablet10 mg/1oralMeda Pharmaceuticals Inc.2009-07-24Not applicableUs
Intermezzotablet1.75 mg/1sublingualPurdue Pharma LP2012-04-05Not applicableUs
Intermezzotablet3.5 mg/1sublingualPurdue Pharma LP2012-04-05Not applicableUs
Ivadaltablet10 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Ivadaltablet5 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Sublinoxtablet (orally disintegrating)5 mgsublingualValeant Canada Lp Valeant Canada S.E.C.2013-01-28Not applicableCanada
Sublinoxtablet (orally disintegrating)10 mgsublingualValeant Canada Lp Valeant Canada S.E.C.2011-11-29Not applicableCanada
Zolpidem Tartratetablet, coated10 mg/1oralKAISER FOUNDATION HOSPITALS2008-10-01Not applicableUs
Zolpidem Tartratetablet, coated5 mg/1oralKAISER FOUNDATION HOSPITALS2008-10-01Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralPhysicians Total Care, Inc.2010-12-16Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralWinthrop U.S, A Business Of Sanofi Aventis U.S. Llc2010-12-06Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralWinthrop U.S, A Business Of Sanofi Aventis U.S. Llc2010-10-14Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralAphena Pharma Solutions Tennessee, Llc2010-12-06Not applicableUs
Zolpidem Tartrate ODTtablet (orally disintegrating)10 mgsublingualValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Zolpidem Tartrate ODTtablet (orally disintegrating)5 mgsublingualValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Zolpimistspray, metered5 mg/1oralECR Pharmaceuticals2010-12-01Not applicableUs
Zolpimistspray, metered5 mg/1oralMagna Pharmaceuticals, Inc.2016-03-21Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-zolpidem ODTtablet (orally disintegrating)5 mgsublingualApotex Inc2015-02-13Not applicableCanada
Apo-zolpidem ODTtablet (orally disintegrating)10 mgsublingualApotex Inc2015-02-13Not applicableCanada
Zolpidemtablet10 mg/1oralWest ward Pharmaceutical Corp2008-04-30Not applicableUs
Zolpidemtablet5 mg/1oralWest ward Pharmaceutical Corp2008-04-30Not applicableUs
Zolpidem Tartratetablet10 mg/1oralMedsource Pharmaceuticals2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-04-27Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralA S Medication Solutions Llc2011-06-07Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralNorth Star Rx Llc2007-05-04Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralUnit Dose Services2011-10-31Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralCardinal Health2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-04-15Not applicableUs
Zolpidem Tartratetablet5 mg/1oralCardinal Health2009-10-14Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralSandoz Inc2011-10-31Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralA S Medication Solutions Llc2010-10-13Not applicableUs
Zolpidem Tartratetablet5 mg/1oralSt Marys Medical Park Pharmacy2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralActavis Pharma, Inc.2011-06-07Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralAurobindo Pharma Limited2007-05-04Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralCardinal Health2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralRoxane Laboratories, Inc2007-04-27Not applicableUs
Zolpidem Tartratetablet5 mg/1oralbryant ranch prepack2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPreferred Pharmaceuticals, Inc.2015-02-23Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralProficient Rx LP2011-10-31Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralNorth Star Rx Llc2007-05-04Not applicableUs
Zolpidem Tartratetablet, coated10 mg/1oralAmerican Health Packaging2014-01-07Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralBlenheim Pharmacal, Inc.2013-10-03Not applicableUs
Zolpidem Tartratetablet1.75 mg/1sublingualNovel Laboratories, Inc.2016-03-22Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralAurobindo Pharma Limited2007-05-04Not applicableUs
Zolpidem Tartratetablet, coated5 mg/1oralSandoz Inc2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
Zolpidem Tartratetablet3.5 mg/1sublingualGAVIS Pharmaceuticals, LLC2016-03-22Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-04-27Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralA S Medication Solutions Llc2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralUnit Dose Services2008-11-21Not applicableUs
Zolpidem Tartratetablet10 mg/1oralCardinal Health2011-01-28Not applicableUs
Zolpidem Tartratetablet10 mg/1oralCardinal Health2009-11-02Not applicableUs
Zolpidem Tartratetablet5 mg/1oralDIRECT RX2015-01-01Not applicableUs
Zolpidem Tartratetablet, extended release6.25 mg/1oralSandoz Inc2011-10-31Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralActavis Pharma, Inc.2010-10-13Not applicableUs
Zolpidem Tartratetablet10 mg/1oralTYA Pharmaceuticals2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralbryant ranch prepack2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPreferred Pharmaceuticals, Inc.2015-02-23Not applicableUs
Zolpidem Tartratetablet5 mg/1oralSTAT Rx USA LLC2007-09-05Not applicableUs
Zolpidem Tartratetablet, coated5 mg/1oralAmerican Health Packaging2014-01-07Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralBlenheim Pharmacal, Inc.2013-10-03Not applicableUs
Zolpidem Tartratetablet3.5 mg/1sublingualNovel Laboratories, Inc.2016-03-22Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-11-21Not applicableUs
Zolpidem Tartratetablet5 mg/1oralRx Change Co.2014-11-27Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralA S Medication Solutions Llc2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralUnit Dose Services2008-11-21Not applicableUs
Zolpidem Tartratetablet5 mg/1oralCardinal Health2011-01-28Not applicableUs
Zolpidem Tartratetablet5 mg/1oralCardinal Health2009-11-02Not applicableUs
Zolpidem Tartratetablet10 mg/1oralDIRECT RX2015-12-02Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralQualitest Pharmaceuticals2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralApotex Corp.2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralKAISER FOUNDATION HOSPITALS2015-09-15Not applicableUs
Zolpidem Tartratetablet10 mg/1oralWockhardt USA LLC.2007-05-15Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralRanbaxy Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet10 mg/1oralSTAT Rx USA LLC2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralRed Pharm Drug Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet10 mg/1oralBlenheim Pharmacal, Inc.2011-03-11Not applicableUs
Zolpidem Tartratetablet10 mg/1oralAmerican Health Packaging2009-10-142015-12-29Us
Zolpidem Tartratetablet10 mg/1oralH.J. Harkins Company, Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralA S Medication Solutions Llc2010-10-13Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralCardinal Health2007-04-232016-03-11Us
Zolpidem Tartratetablet, film coated10 mg/1oralDr. Reddy's Laboratories Limited2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralQualitest Pharmaceuticals2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralApotex Corp.2007-04-23Not applicableUs
Zolpidem Tartratetablet5 mg/1oralWockhardt USA LLC.2007-05-15Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralRanbaxy Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet5 mg/1oralPreferred Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet10 mg/1oralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Zolpidem Tartratetablet10 mg/1oralRed Pharm Drug Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet5 mg/1oralAmerican Health Packaging2009-10-142015-12-29Us
Zolpidem Tartratetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet10 mg/1oralRx Change Co.2014-11-20Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralWatson Laboratories, Inc.2013-03-25Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralWockhardt Limited2007-05-15Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2011-06-01Not applicableUs
Zolpidem Tartratetablet10 mg/1oralProficient Rx LP2007-09-05Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralLupin Pharmaceuticals, Inc.2014-04-07Not applicableUs
Zolpidem Tartratetablet5 mg/1oralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Zolpidem Tartratetablet5 mg/1oralRed Pharm Drug Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralMc Kesson Contract Packaging2011-10-21Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet10 mg/1oralAidarex Pharmaceuticals LLC2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-06-10Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralA S Medication Solutions Llc2011-06-07Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralCardinal Health2007-04-232016-03-11Us
Zolpidem Tartratetablet, film coated5 mg/1oralDr. Reddy's Laboratories Limited2007-04-23Not applicableUs
Zolpidem Tartratetablet, extended release6.25 mg/1oralLupin Pharmaceuticals, Inc.2014-04-07Not applicableUs
Zolpidem Tartratetablet10 mg/1oralApotheca, Inc2007-09-25Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralRed Pharm Drug, Inc.2007-05-04Not applicableUs
Zolpidem Tartratetablet10 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralREMEDYREPACK INC.2016-02-12Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralMc Kesson Contract Packaging2011-10-20Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralProficient Rx LP2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-10Not applicableUs
Zolpidem Tartratetablet5 mg/1oralAidarex Pharmaceuticals LLC2007-09-05Not applicableUs
Zolpidem Tartratetablet10 mg/1oralREMEDYREPACK INC.2013-05-22Not applicableUs
Zolpidem Tartratetablet10 mg/1oralA S Medication Solutions Llc2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralCardinal Health2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralPhysicians Total Care, Inc.2010-11-02Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-12-16Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralWatson Laboratories, Inc.2013-03-25Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralWockhardt Limited2007-05-15Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralbryant ranch prepack2008-11-21Not applicableUs
Zolpidem Tartratetablet5 mg/1oralProficient Rx LP2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPreferred Pharmaceuticals Inc.2016-01-11Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralSTAT Rx USA LLC2008-11-21Not applicableUs
Zolpidem Tartratetablet10 mg/1oralRebel Distributors Corp.2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralMylan Institutional Inc.2007-05-01Not applicableUs
Zolpidem Tartratetablet5 mg/1oralA S Medication Solutions Llc2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralCardinal Health2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2009-07-01Not applicableUs
Zolpidem Tartratetablet10 mg/1oralCarlsbad Technology, Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-10Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc2007-04-23Not applicableUs
Zolpidem Tartratetablet, extended release6.25 mg/1oralbryant ranch prepack2011-10-31Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralProficient Rx LP2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Zolpidem Tartratetablet5 mg/1oralApotheca, Inc2007-07-25Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralDispensing Solutions, Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet5 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Zolpidem Tartratetablet5 mg/1oralPd Rx Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralLife Line Home Care Services, Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-13Not applicableUs
Zolpidem Tartratetablet5 mg/1oralRebel Distributors Corp.2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralMylan Institutional Inc.2007-05-01Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-11-07Not applicableUs
Zolpidem Tartratetablet10 mg/1oralCardinal Health2009-10-14Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPhysicians Total Care, Inc.2007-10-09Not applicableUs
Zolpidem Tartratetablet5 mg/1oralCarlsbad Technology, Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralRoxane Laboratories, Inc2007-04-27Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralbryant ranch prepack2011-10-31Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralProficient Rx LP2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralAmerican Health Packaging2011-12-01Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralBlenheim Pharmacal, Inc.2011-01-07Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralDispensing Solutions, Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet, coated10 mg/1oralSandoz Inc2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPreferred Pharmaceuticals Inc.2016-01-20Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
Zolpidem Tartratetablet1.75 mg/1sublingualGAVIS Pharmaceuticals, LLC2016-03-22Not applicableUs
Zolpidem Tartrate Extended Releasetablet, film coated, extended release12.5 mg/1oralSt Marys Medical Park Pharmacy2013-01-10Not applicableUs
Zolpidem Tartrate Extended-releasetablet, film coated, extended release12.5 mg/1oralAvera Mc Kennan Hospital2015-06-29Not applicableUs
Zolpidem Tartrate Extended-releasetablet, film coated, extended release6.25 mg/1oralPar Pharmaceutical, Inc.2011-04-14Not applicableUs
Zolpidem Tartrate Extended-releasetablet, film coated, extended release12.5 mg/1oralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Zolpidem Tartrate Extended-releasetablet, film coated, extended release12.5 mg/1oralPar Pharmaceutical, Inc.2011-12-06Not applicableUs
Zolpidem Tartrate Extended-releasetablet, film coated, extended release6.25 mg/1oralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdormixSanofi Pasteur
Bikalmsanofi-aventis
Dormizolsanofi-aventis
HypnogenZentiva
IvedalWinthrop
NasenPolfarmex
NimadormSandoz
Nottemsanofi-aventis
Stilnoctsanofi-aventis
Stilnoxsanofi-aventis
Stilnox CRsanofi-aventis
ZolsanaKrka
ZoltisBiofarm
Brand mixtures
NameLabellerIngredients
Gabazolpidem-5Physician Therapeutics Llc
Sentrazolpidem PM-5Physician Therapeutics Llc
Salts
Name/CASStructureProperties
Zolpidem tartrate
ThumbNot applicableDBSALT001047
Categories
UNII7K383OQI23
CAS number82626-48-0
WeightAverage: 307.3895
Monoisotopic: 307.168462309
Chemical FormulaC19H21N3O
InChI KeyInChIKey=ZAFYATHCZYHLPB-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
IUPAC Name
N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
SMILES
CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylimidazoles. These are polycyclic aromatic compounds containing a benzene ring linked to an imidazole ring through a CC or CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassImidazoles
Direct ParentPhenylimidazoles
Alternative Parents
Substituents
  • 4-phenylimidazole
  • 5-phenylimidazole
  • Imidazopyridine
  • Methylpyridine
  • Toluene
  • Benzenoid
  • Pyridine
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the short-term treatment of insomnia.
PharmacodynamicsZolpidem is a sedative or hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties. It interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all three alpha receptor subtypes, zolpidem in vitro binds the (alpha1) receptor preferentially. The (alpha1) receptor is found primarily on the Lamina IV of the sensorimotor cortical regions, substantia nigra (pars reticulata), cerebellum molecular layer, olfactory bulb, ventral thalamic complex, pons, inferior colliculus, and globus pallidus.
Mechanism of actionZolpidem modulates the alpha-subunit, known as the benzodiazepine receptor, within the GABAA receptor chloride channel macromolecular complex. Unlike the benzodiazepines, which non-selectively interact with all three alpha-receptor subtypes, Zolpidem preferentially binds to the alpha-1 receptor.
Related Articles
AbsorptionZolpidem is rapidly absorbed from the GI tract.
Volume of distributionNot Available
Protein binding92.5 ± 0.1% (independent of concentration between 40 and 790 ng/mL)
Metabolism

Zolpidem is converted to inactive metabolites in the liver.

SubstrateEnzymesProduct
Zolpidem
Methoxyzolpidem derivative (M3)Details
Zolpidem
Methoxyzolpidem derivative (M4)Details
Zolpidem
Not Available
Methoxyzolpidem derivative (M11)Details
Methoxyzolpidem derivative (M4)
Not Available
Zolpidem carboxylic acid derivative (M2)Details
Methoxyzolpidem derivative (M3)
Not Available
Zolpidem carboxylic acid derivative (M1)Details
Route of eliminationZolpidem tartrate tablets are converted to inactive metabolites that are eliminated primarily by renal excretion.
Half life2.6 hours
ClearanceNot Available
ToxicityOral (male rat) LD50 = 695 mg/kg. Symptoms of overdose include impairment of consciousness ranging from somnolence to light coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9392
Caco-2 permeable+0.6638
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.7574
Renal organic cation transporterNon-inhibitor0.621
CYP450 2C9 substrateNon-substrate0.7412
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateInhibitor0.624
CYP450 2C9 inhibitorNon-inhibitor0.8331
CYP450 2D6 inhibitorNon-inhibitor0.8754
CYP450 2C19 inhibitorNon-inhibitor0.9119
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5265
Ames testNon AMES toxic0.5507
CarcinogenicityNon-carcinogens0.8352
BiodegradationNot ready biodegradable0.9928
Rat acute toxicity2.5614 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9831
hERG inhibition (predictor II)Non-inhibitor0.6928
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novadel pharma inc
  • Sanofi aventis us llc
  • Biovail laboratories international srl
  • Apotex inc
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Carlsbad technology inc
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Hikma pharmaceuticals
  • Invagen pharmaceuticals inc
  • Lek pharmaceuticals dd
  • Mutual pharmacal co
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Synthon pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Torrent pharmaceuticals ltd
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Wockhardt ltd
  • World gen llc
  • Meda pharmaceuticals
  • Pfizer inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral5 mg/1
Tabletoral6.25 mg/1
Tablet, coatedoral12.5 mg/1
Tablet, coatedoral6.25 mg/1
Tablet (orally disintegrating)sublingual10 mg
Tablet (orally disintegrating)sublingual5 mg
Tabletoral10 mg/1
Tabletoral5 mg/1
Kit
Tabletsublingual1.75 mg/1
Tabletsublingual3.5 mg/1
Tabletoral10 mg
Tabletoral5 mg
Kitoral
Tablet, coatedoral10 mg/1
Tablet, coatedoral5 mg/1
Tablet, extended releaseoral12.5 mg/1
Tablet, extended releaseoral6.25 mg/1
Tablet, film coated, extended releaseoral12.5 mg/1
Tablet, film coated, extended releaseoral6.25 mg/1
Spray, meteredoral5 mg/1
Prices
Unit descriptionCostUnit
Ambien cr 12.5 mg tablet6.19USD tablet
Ambien cr 6.25 mg tablet6.19USD tablet
Ambien 10 mg tablet6.11USD tablet
Ambien 5 mg tablet6.04USD tablet
Ambien CR 12.5 mg Controlled Release Tabs6.0USD tab
Ambien CR 6.25 mg Controlled Release Tabs6.0USD tab
Edluar 10 mg sl tablet5.0USD tablet
Edluar 5 mg sl tablet5.0USD tablet
Zolpidem tartrate 10 mg tablet2.73USD tablet
Zolpidem tartrate 5 mg tablet2.73USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6514531 Yes2000-06-012020-06-01Us
US6761910 No1999-09-242019-09-24Us
US7632517 No1997-10-012017-10-01Us
US7658945 No2007-04-152027-04-15Us
US7682628 No2005-02-162025-02-16Us
US8242131 No2009-08-202029-08-20Us
US8252809 No2005-02-162025-02-16Us
US8512747 No1999-09-242019-09-24Us
US9265720 No2010-05-132030-05-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point196 °CPhysProp
water solubility23 mg/mLNot Available
logP1.2Not Available
pKa6.2MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0313 mg/mLALOGPS
logP3.15ALOGPS
logP3.02ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)5.65ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity93.58 m3·mol-1ChemAxon
Polarizability35.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-000i-1090000000-5429f5620534a2340098View in MoNA
References
Synthesis Reference

Markus Sauter, “Process for preparing zolpidem.” U.S. Patent US20020183522, issued December 05, 2002.

US20020183522
General References
  1. Lemmer B: The sleep-wake cycle and sleeping pills. Physiol Behav. 2007 Feb 28;90(2-3):285-93. Epub 2006 Oct 16. [PubMed:17049955 ]
  2. Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G: Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther. 1986 May;237(2):649-58. [PubMed:2871178 ]
  3. Clauss RP, Guldenpfennig WM, Nel HW, Sathekge MM, Venkannagari RR: Extraordinary arousal from semi-comatose state on zolpidem. A case report. S Afr Med J. 2000 Jan;90(1):68-72. [PubMed:10721397 ]
  4. Schlich D, L'Heritier C, Coquelin JP, Attali P, Kryrein HJ: Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res. 1991 May-Jun;19(3):271-9. [PubMed:1670039 ]
  5. Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL: The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res. 1992 Apr;20(2):162-70. [PubMed:1521672 ]
External Links
ATC CodesN05CF02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (323 KB)
MSDSDownload (170 KB)
Interactions
Drug Interactions
Drug
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
AprepitantThe serum concentration of Zolpidem can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
AzelastineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
BexaroteneThe serum concentration of Zolpidem can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Zolpidem can be decreased when it is combined with Bosentan.
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
BuprenorphineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
CarbamazepineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ConivaptanThe serum concentration of Zolpidem can be increased when it is combined with Conivaptan.
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DabrafenibThe serum concentration of Zolpidem can be decreased when it is combined with Dabrafenib.
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DasatinibThe serum concentration of Zolpidem can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Zolpidem can be decreased when it is combined with Deferasirox.
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Dexchlorpheniramine maleateDexchlorpheniramine maleate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
EthanolZolpidem may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
FluconazoleThe metabolism of Zolpidem can be decreased when combined with Fluconazole.
FlumazenilFlumazenil may decrease the sedative activities of Zolpidem.
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
FosaprepitantThe serum concentration of Zolpidem can be increased when it is combined with Fosaprepitant.
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Fusidic AcidThe serum concentration of Zolpidem can be increased when it is combined with Fusidic Acid.
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
HydrocodoneZolpidem may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
IdelalisibThe serum concentration of Zolpidem can be increased when it is combined with Idelalisib.
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ItraconazoleThe serum concentration of Zolpidem can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Zolpidem can be increased when it is combined with Ivacaftor.
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
KetoconazoleThe serum concentration of Zolpidem can be increased when it is combined with Ketoconazole.
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
LuliconazoleThe serum concentration of Zolpidem can be increased when it is combined with Luliconazole.
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MethotrimeprazineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MetyrosineZolpidem may increase the sedative activities of Metyrosine.
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MifepristoneThe serum concentration of Zolpidem can be increased when it is combined with Mifepristone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MitotaneThe serum concentration of Zolpidem can be decreased when it is combined with Mitotane.
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
NelfinavirThe metabolism of Zolpidem can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Zolpidem can be increased when it is combined with Netupitant.
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
OrphenadrineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PalbociclibThe serum concentration of Zolpidem can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ParaldehydeZolpidem may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Paroxetine.
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PosaconazoleThe serum concentration of Zolpidem can be increased when it is combined with Posaconazole.
PramipexoleZolpidem may increase the sedative activities of Pramipexole.
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
RifabutinThe serum concentration of Zolpidem can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Zolpidem can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Zolpidem can be decreased when it is combined with Rifapentine.
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
RopiniroleZolpidem may increase the sedative activities of Ropinirole.
RotigotineZolpidem may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Zolpidem.
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Scopolamine butylbromideScopolamine butylbromide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
SiltuximabThe serum concentration of Zolpidem can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Zolpidem can be increased when it is combined with Simeprevir.
Sodium oxybateZolpidem may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
St. John's WortThe serum concentration of Zolpidem can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Zolpidem can be increased when it is combined with Stiripentol.
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
SuvorexantZolpidem may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TelaprevirThe serum concentration of Zolpidem can be decreased when it is combined with Telaprevir.
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ThalidomideZolpidem may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TocilizumabThe serum concentration of Zolpidem can be decreased when it is combined with Tocilizumab.
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
VoriconazoleThe serum concentration of Zolpidem can be increased when it is combined with Voriconazole.
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Avoid alcohol.
  • Should not be administered with or immediately after a meal.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Vlainic J, Pericic D: Effects of acute and repeated zolpidem treatment on pentylenetetrazole-induced seizure threshold and on locomotor activity: comparison with diazepam. Neuropharmacology. 2009 Jun;56(8):1124-30. doi: 10.1016/j.neuropharm.2009.03.010. Epub 2009 Apr 1. [PubMed:19345234 ]
  4. Smith AJ, Alder L, Silk J, Adkins C, Fletcher AE, Scales T, Kerby J, Marshall G, Wafford KA, McKernan RM, Atack JR: Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol. 2001 May;59(5):1108-18. [PubMed:11306694 ]
  5. Pritchett DB, Seeburg PH: Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem. 1990 May;54(5):1802-4. [PubMed:2157817 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Pritchett DB, Seeburg PH: Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem. 1990 May;54(5):1802-4. [PubMed:2157817 ]
  2. Smith AJ, Alder L, Silk J, Adkins C, Fletcher AE, Scales T, Kerby J, Marshall G, Wafford KA, McKernan RM, Atack JR: Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol. 2001 May;59(5):1108-18. [PubMed:11306694 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Pritchett DB, Seeburg PH: Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem. 1990 May;54(5):1802-4. [PubMed:2157817 ]
  2. Smith AJ, Alder L, Silk J, Adkins C, Fletcher AE, Scales T, Kerby J, Marshall G, Wafford KA, McKernan RM, Atack JR: Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol. 2001 May;59(5):1108-18. [PubMed:11306694 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 25, 2016 03:19